US Stock MarketDetailed Quotes
KROS Keros Therapeutics
- 51.850
- -0.430-0.82%
Trading May 20 13:32 ET
1.87BMarket Cap-10067P/E (TTM)
52.945High51.385Low96.51KVolume52.700Open52.280Pre Close5.01MTurnover0.31%Turnover RatioLossP/E (Static)36.08MShares73.00052wk High4.12P/B1.60BFloat Cap27.02052wk Low--Dividend TTM30.95MShs Float88.800Historical High--Div YieldTTM2.98%Amplitude19.100Historical Low51.926Avg Price1Lot Size
About Keros Therapeutics Company
Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. The company was founded in 2015 and is headquartered in Lexington, MA.
Company Profile
SymbolKROS
Company NameKeros Therapeutics
Listing DateApr 8, 2020
Issue Price16.00
Founded2015
CEODr. Jasbir Seehra, PhD
MarketNASDAQ
Employees136
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address1050 Waltham Street,Suite 302
CityLexington
ProvinceMassachusetts
CountryUnited States of America
Zip Code02421
Phone1-617-314-6297
Websitehttp://www.kerostx.com
Company Executives
- Name
- Position
- Salary
- Dr. Jasbir Seehra, PhD
- Chief Executive Officer and Director
- 8.93M
- Keith Regnante
- Chief Financial Officer and Principal Accounting Officer
- 2.20M
- Christopher Rovaldi
- Chief Operating Officer
- 4.69M
- Dr. Carl L. Gordon, C.F.A.,PhD
- Chairman of the Board
- 409.37K
- Ran Nussbaum
- Independent Director
- 390.56K
- Nima Farzan
- Independent Director
- 388.48K
- Dr. Alpna Seth, PhD
- Independent Director
- 1.02M
- Julius Knowles
- Independent Director
- 388.48K
- Tomer Kariv
- Independent Director
- 385.86K
- Dr. Mary Ann Gray,PhD
- Independent Director
- 396.98K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg